GE Healthcare’s Biosafe announces Sefia platform to address multiple steps in cell therapy production process

CHALFONT ST. GILES, UK – At the International Society for Cellular Therapy’s Regional Meeting in Memphis, TN, GE Healthcare’s recently acquired Biosafe Group introduces Sefia, a state-of-the-art, multi-function platform which uses a combination of continuous-flow centrifugation, temperature control and fluidic management to enable purification, concentration, washing and final formulation during cell processing. Combined with GE Healthcare’s existing portfolio, Sefia further advances access to a single-solution manufacturing platform to enable turnkey, scalable manufacturing of cell therapies.

Sefia is a functionally-closed laboratory instrument, CE certified for safety compliance with IEC 61010, IEC 61 326, and IEC 62304 standards, and designed for use in good automated manufacturing practice (GAMP)-compliant environments. Harnessing two new technologies—along with smart process control, temperature regulation and eight separate fluid pathways—Sefia performs simple and complex manipulatio

< | >